You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIDespite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
2-HOBA for Treatment of Pulmonary Hypertension
SBC: MTI Biotech Incorporated Topic: NHLBIPROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects
SBC: General Biophysics LLC Topic: NIAPHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent
SBC: PACDNA LLC Topic: NCIProject Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia
SBC: HOPEFUL AGING LLC Topic: RPROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, and Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly impact ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An Interactive Education Program to Reduce High Risk Behavior in Adolescents
SBC: KLEIN BUENDEL, INC. Topic: NICHDInternet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
SBC: ROCK IMMUNE LLC Topic: 102Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
SBC: AQUALUNG THERAPEUTICS, CORP Topic: 300ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Fast and Radiation Hard Scintillators for High Dose Detection
SBC: RADIATION MONITORING DEVICES, INC. Topic: DTRA20B001The event of nuclear explosion generates harsh radiation conditions, evaluation of which is critical in protecting the military and civilian personnel from serious harm. Due to these harsh conditions only very simple methods of radiation assessment are employed, such as measurement of equivalent dose. Improvements to current instrumentation are sought that would provide energy resolved dose in ...
STTR Phase II 2023 Department of DefenseDefense Threat Reduction Agency